Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Staib

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Vaccine|April 17, 2007
Recombinant murine gammaherpesvirus 68 (MHV-68) as challenge virus to test efficacy of vaccination against chronic virus infections in the mouse modelSusanne El-Gogo, Caroline Staib, Marcus Meyr, et al.
Vaccine|September 23, 2008
A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirusKia Schulze, Caroline Staib, Hermann M Schätzl, et al.
Journal of Virology|July 15, 2003
Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3LSimone Hornemann, Olof Harlin, Caroline Staib, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 22, 2005
Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccinesAntje Heit, Frank Schmitz, Meredith O'Keeffe, et al.
Journal of Virological Methods|November 29, 2008
Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selectionGiulia Di Lullo, Elisa Soprana, Maddalena Panigada, et al.
The Journal of General Virology|October 23, 2009
Viral host-range factor C7 or K1 is essential for modified vaccinia virus Ankara late gene expression in human and murine cells, irrespective of their capacity to inhibit protein kinase R-mediated phosphorylation of eukaryotic translation initiation factor 2alphaSimone Backes, Karin M Sperling, Joachim Zwilling, et al.
World Journal of Gastroenterology|June 5, 2002
Full-length core sequence dependent complex-type glycosylation of hepatitis C virus E2 glycoproteinLi-Xin Zhu, Jing Liu, Ying-Chun Li, et al.
Clinical and Diagnostic Laboratory Immunology|March 12, 2004
Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virusAntonio Cosma, Silja Bühler, Rashmi Nagaraj, et al.
AIDS Research and Human Retroviruses|July 3, 2007
Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAARTAntonio Cosma, Rashmi Nagaraj, Caroline Staib, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 9, 2003
Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccinesIngo Drexler, Caroline Staib, Wolfgang Kastenmuller, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Vaccine|April 17, 2007
Recombinant murine gammaherpesvirus 68 (MHV-68) as challenge virus to test efficacy of vaccination against chronic virus infections in the mouse modelSusanne El-Gogo, Caroline Staib, Marcus Meyr, et al.
Vaccine|September 23, 2008
A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirusKia Schulze, Caroline Staib, Hermann M Schätzl, et al.
Journal of Virology|July 15, 2003
Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3LSimone Hornemann, Olof Harlin, Caroline Staib, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 22, 2005
Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccinesAntje Heit, Frank Schmitz, Meredith O'Keeffe, et al.
Journal of Virological Methods|November 29, 2008
Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selectionGiulia Di Lullo, Elisa Soprana, Maddalena Panigada, et al.
The Journal of General Virology|October 23, 2009
Viral host-range factor C7 or K1 is essential for modified vaccinia virus Ankara late gene expression in human and murine cells, irrespective of their capacity to inhibit protein kinase R-mediated phosphorylation of eukaryotic translation initiation factor 2alphaSimone Backes, Karin M Sperling, Joachim Zwilling, et al.
World Journal of Gastroenterology|June 5, 2002
Full-length core sequence dependent complex-type glycosylation of hepatitis C virus E2 glycoproteinLi-Xin Zhu, Jing Liu, Ying-Chun Li, et al.
Clinical and Diagnostic Laboratory Immunology|March 12, 2004
Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virusAntonio Cosma, Silja Bühler, Rashmi Nagaraj, et al.
AIDS Research and Human Retroviruses|July 3, 2007
Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAARTAntonio Cosma, Rashmi Nagaraj, Caroline Staib, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 9, 2003
Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccinesIngo Drexler, Caroline Staib, Wolfgang Kastenmuller, et al.
Pageof 3